Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Aims: To study the prevalence of unknown atrial fibrillation (AF) in a high-risk, 75/76-year-old, population using N-terminal B-type natriuretic peptide (NT-proBNP) and handheld electrocardiogram (ECG) recordings in a stepwise screening procedure. Methods and results: The STROKESTOP II study is a population-based cohort study in which all 75/76-year-old in the Stockholm region (n = 28 712) were randomized 1:1 to be invited to an AF screening programme or to serve as the control group. Participants without known AF had NT-proBNP analysed and were stratified into low-risk (NT-proBNP <125 ng/L) and high-risk (NT-proBNP ≥125 ng/L) groups. The high-risk group was offered extended ECG-screening, whereas the low-risk group performed only one single-lead ECG recording. In total, 6868 individuals accepted the screening invitation of which 6315 (91.9%) did not have previously known AF. New AF was detected in 2.6% [95% confidence interval (CI) 2.2–3.0] of all participants without previous AF. In the high-risk group (n = 3766/6315, 59.6%), AF was diagnosed in 4.4% (95% CI 3.7–5.1) of the participants. Out of these, 18% had AF on their index-ECG. In the low-risk group, one participant was diagnosed with AF on index-ECG. The screening procedure resulted in an increase in known prevalence from 8.1% to 10.5% among participants. Oral anticoagulant treatment was initiated in 94.5% of the participants with newly diagnosed AF. Conclusion: N-terminal B-type natriuretic peptide-stratified systematic screening for AF identified 4.4% of the high-risk participants with new AF. Oral anticoagulant treatment initiation was well accepted in the group diagnosed with new AF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
External review and validation of the Swedish national inpatient register
Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.-L., Reuterwall, C., Heurgren, M., & Olausson, P. O. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-450 · Cited by 5,055
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793 · cited 1×
“Oral anticoagulant (OAC) treatment reduces stroke-risk by 60–70% in individuals at increased risk.(3) Since AF is a common, chronic and progressive and commonly asymptomatic disease, with increased risk of serious but treatable complications it meets most of the World Health Organization’s criteria for population scre…”
BackgroundSubclinical atrial fibrillation and the risk of stroke
Healey, J. S., Connolly, S. J., Gold, M. R., Israel, C. W., Van Gelder, I. C., Capucci, A., Lau, C. P., Fain, E., Yang, S., Bailleul, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105575 · Cited by 2,100
Olesen, J. B., Lip, G. Y. H., Hansen, M. L., Hansen, P. R., Tolstrup, J. S., Lindhardsen, J., Selmer, C., Ahlehoff, O., Olsen, A.-M. S., Gislason, G. H., et al. (2011) · BMJ · doi:10.1136/bmj.d124 · Cited by 1,428
Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study
Svennberg, E., Engdahl, J., Al-Khalili, F., Friberg, L., Frykman, V., & Rosenqvist, M. (2015) · Circulation · doi:10.1161/circulationaha.114.014343 · Cited by 605
Halcox, J. P. J., Wareham, K., Cardew, A., Gilmore, M., Barry, J. P., Phillips, C., & Gravenor, M. B. (2017) · Circulation · doi:10.1161/circulationaha.117.030583 · Cited by 580 · cited 2×
“A similarly low proportion of unreadable recordings was reported from the REHEARSE-AF trial.(16) Using the validated ECG-interpreting algorithm,(12) the ECG-interpreting workload was reduced by over 85% compared to the STROKESTOP I trial.”
MethodResultHijazi, Z., Oldgren, J., Andersson, U., Connolly, S. J., Ezekowitz, M. D., Hohnloser, S. H., Reilly, P. A., Vinereanu, D., Siegbahn, A., Yusuf, S., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.038729 · Cited by 402 · cited 5×
“Although the low-risk group was not investigated with repeated ECG recordings and hence there is risk of undetected AF in that group, the proportion of participants diagnosed with AF on index ECG was markedly higher in the high-risk group, suggesting the discriminative performance of NT-proBNP.”
BackgroundInfluentialSavelieva, I., & Camm, A. J. (2000) · Journal of Interventional Cardiac Electrophysiology · doi:10.1023/a:1009823001707 · Cited by 339
Screening to identify unknown atrial fibrillation: A systematic review
Lowres, N., Neubeck, L., Redfern, J., & Freedman, S. B. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-02-0165 · Cited by 327
Patton, K. K., Ellinor, P. T., Heckbert, S. R., Christenson, R. H., DeFilippi, C., Gottdiener, J. S., & Kronmal, R. A. (2009) · Circulation · doi:10.1161/circulationaha.109.873265 · Cited by 310 · cited 2×
“N-terminal B-type natriuretic peptide has repeatedly been shown to be one of the strongest predictors for AF development.(6) When adding NT-proBNP to the multivariable analyses, heart failure became an insignificant factor for AF prediction.”
BackgroundMethodEngdahl, J., Andersson, L., Mirskaya, M., & Rosenqvist, M. (2013) · Circulation · doi:10.1161/circulationaha.112.126656 · Cited by 233
Self-citationAronsson, M., Svennberg, E., Rosenqvist, M., Engdahl, J., Al-Khalili, F., Friberg, L., Frykman-Kull, V., & Levin, L.-Å. (2015) · Europace · doi:10.1093/europace/euv083 · Cited by 154
Improved screening for silent atrial fibrillation after ischaemic stroke
Doliwa Sobocinski, P., Anggardh Rooth, E., Frykman Kull, V., von Arbin, M., Wallen, H., & Rosenqvist, M. (2012) · Europace · doi:10.1093/europace/eur431 · Cited by 112
Self-citationShort-term ECG for out of hospital detection of silent atrial fibrillation episodes
Doliwa, P. S., Frykman, V., & Rosenqvist, M. (2009) · Scandinavian Cardiovascular Journal · doi:10.1080/14017430802593435 · Cited by 105
Self-citationFriberg, L., Engdahl, J., Frykman, V., Svennberg, E., Levin, L.-Å., & Rosenqvist, M. (2013) · EP Europace · doi:10.1093/europace/eus217 · Cited by 100
Self-citation
Cited by
Van Gelder, I. C., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J. G. M., De Potter, T. J. R., Dwight, J., Guasti, L., Hanke, T., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae176 · Cited by 3,024
Self-citationSvennberg, E., Friberg, L., Frykman, V., Al-Khalili, F., Engdahl, J., & Rosenqvist, M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01637-8 · Cited by 358
Self-citationMultilevel omics for the discovery of biomarkers and therapeutic targets for stroke
Montaner, J., Ramiro, L., Simats, A., Tiedt, S., Makris, K., Jickling, G. C., Debette, S., Sanchez, J.-C., & Bustamante, A. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0350-6 · Cited by 330
How to use digital devices to detect and manage arrhythmias: an EHRA practical guide
Svennberg, E., Tjong, F., Goette, A., Akoum, N., Di Biase, L., Bordachar, P., Boriani, G., Burri, H., Conte, G., Deharo, J. C., et al. (2022) · Europace · doi:10.1093/europace/euac038 · Cited by 261
Self-citationNielsen, J. C., Lin, Y.-J., de Oliveira Figueiredo, M. J., Sepehri Shamloo, A., Alfie, A., Boveda, S., Dagres, N., Di Toro, D., Eckhardt, L. L., Ellenbogen, K., et al. (2020) · EP Europace · doi:10.1093/europace/euaa065 · Cited by 98
Metadata
- Authors
- Kemp Gudmundsdottir, K., Fredriksson, T., Svennberg, E., Al-Khalili, F., Friberg, L., Frykman, V., Hijazi, Z., Rosenqvist, M., & Engdahl, J.
- Venue
- EP Europace
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-09-17
- Volume
- 22
- Issue
- 1
- Pages
- 24-32
- ISSN
- 1099-5129 (ISSN-L)
- 1532-2092
- OpenAlex
- W2566015711
- Cited by
- 130
- References
- 16
- FWCI
- 11.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.